Results 201 to 210 of about 25,222 (249)
Some of the next articles are maybe not open access.
Reactions Weekly, 2023
Abstract Use of opioid antagonists, particularly when delivered as an extended-release formulation, is a meaningful treatment option for individuals with opioid use disorder who are highly motivated to remain opioid abstinent or do not have access to agonist treatment.
Marina Tsoy-Podosenin, Evgeny Krupitsky
+4 more sources
Abstract Use of opioid antagonists, particularly when delivered as an extended-release formulation, is a meaningful treatment option for individuals with opioid use disorder who are highly motivated to remain opioid abstinent or do not have access to agonist treatment.
Marina Tsoy-Podosenin, Evgeny Krupitsky
+4 more sources
Blood naltrexone levels over time following naltrexone implant [PDF]
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008 Aims: Oral naltrexone is used in the management of both heroin and alcohol dependence. However, poor compliance has limited its clinical utility. The study's objective was to determine the period of therapeutic coverage (= 2 ng/ml) provided by a 3.3 g ...
Gary Hulse, Robert J Tait
exaly +3 more sources
Naltrexone and Conventionality
The American Journal of Drug and Alcohol Abuse, 1978This study examines the effect of conventionality on whether patients who were scheduled for naltrexone took it, and on treatment outcomes for patients who did take it. It is based on admission and case record data for 147 male opiate addicts who enrolled in New York Medical College's Multitrack Abstinence Program. Naltrexone-taking is examined against
F, Suffet +3 more
openaire +2 more sources
CNS Drugs, 2010
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to severe pain.
Sean T, Duggan, Lesley J, Scott
openaire +2 more sources
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to severe pain.
Sean T, Duggan, Lesley J, Scott
openaire +2 more sources
Retention in naltrexone implant treatment for opioid dependence
Drug and Alcohol Dependence, 2010 Background: Naltrexone's usefulness in the treatment of opioid dependence stems from its ability to block the action of heroin and other opioids. However, many patients are ambivalent towards naltrexone and often drop out of treatment with orally ...
Nikolaj Kunøe +2 more
exaly +2 more sources
1981
The clinical efficacy of naltrexone together with psychotherapy was compared to that of naltrexone alone in 22 detoxified heroin addicts. The combination of treatments fostered better retention in treatment and greater likelihood of opiate abstinence than naltrexone alone.
N, Stone-Washton +2 more
openaire +2 more sources
The clinical efficacy of naltrexone together with psychotherapy was compared to that of naltrexone alone in 22 detoxified heroin addicts. The combination of treatments fostered better retention in treatment and greater likelihood of opiate abstinence than naltrexone alone.
N, Stone-Washton +2 more
openaire +2 more sources
Journal of Substance Abuse Treatment, 1985
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
openaire +2 more sources
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
openaire +2 more sources
NALTREXONE IN CHILDREN WITH AUTISM
Journal of the American Academy of Child & Adolescent Psychiatry, 1998Item does not contain ...
J K, Buitelaar +2 more
openaire +2 more sources